New Anti-VEGF Drug Promising for Wet Macular Degeneration

Source: Medscape

A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new research shows, according to a report in Medscape.

The experimental drug could improve the potency of currently approved VEGF inhibitors because it suppresses different forms of VEGF, said Pravin Dugel, MD, clinical professor at the Keck School of Medicine in Los Angeles and managing partner at Retinal Consultants of Arizona.

Read the full article here.

Related Content